ArticleFrontiers in cell and developmental biology2022

OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants.

Estelle Colin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.